The Department for Health and Social Care has asked NICE to conduct an appraisal of lisocabtagene maraleucel for treating relapsed or refractory aggressive B-cell non-Hodgkin lymphoma.
Please note that following a regulatory update from the company, the timelines for this appraisal have been revised and technical engagement is now anticipated to begin in late April 2021.